Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of CKD-383 vs Co-administration in Healthy Subjects
NCT05897216Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lobeglitazone, sitagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum Plasma Concentration at 48 hours and Area Under the Concentration-Time Curve at 48 hours. Started Jul 2023; status: completed.
02
Drugs
lobeglitazonesitagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05897216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05897216.